Quantcast
Last updated on April 18, 2014 at 9:27 EDT

Oncology Robotics Live Patient Doses. Health Robotics: 343,815 Doses; Intelligent Hospital Systems/RIVA: 1 Dose

January 21, 2013

BOZEN, Sud-Tirol, Italy, January 21, 2013 /PRNewswire/ –

Health Robotics reported today that it conducted a retrospective review of records for
all “live” patient doses at its global Oncology Robot customers as of December 4, 2012,
right after Intelligent Hospital Systems announced that their RIVA medical device had
produced that same day its “first-ever chemotherapy patient dose”.

Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated:
“As of December 4, 2012, and not including the old generation robots with patents licensed
to Loccioni [APOTECAchemo], Health Robotics “live patients” experience with both its 1st
generation and 2nd generation robots were 343,200 doses on the old CytoCare technology,
and 615 doses on the new i.v.STATION platform, for a total of 343,815 doses compared to 1
total chemo dose for RIVA. This sets the record straight after RIVA’s much ballyhooed
announcement last month, especially if compared with Health Robotics’ proven “live”
support for 60 chemotherapy and monoclonal antibody therapy active ingredients[1].”

Health-System Pharmacists are still questioning why it took so long for RIVA to make
its first-ever chemotherapy dose at Princess Margaret Cancer Centre [Toronto], especially
given the fact that IHS’ precursor (Technology 2000) announced the chemotherapy robot as
far back as a 1989 ASHP Journal article[2]. Moreover, IHS issued many chemotherapy
installation news[3] releases at University of California San Francisco (12/2006, and same
hospital again in 12/2009), Fresenius Kabi (02/2009), Royal Victoria in Barrie, Canada
(01/2010), and Baxter Australia (02/2010). What really happened to all these other RIVA
chemotherapy installations that had been waiting for many years before Princess Margaret?
Why St. Boniface Hospital in Winnipeg has yet to implement its own 1989 invention after
all these years? Should hospitals really expect 5+ years RIVA installation cycles?

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world
[including over 90% the Oncology Robots global market], Health Robotics is the undisputed
leading supplier of life-critical intravenous medication robots, providing over 300
hospital installations in 5 continents with the only fully-integrated robotics-based
technology, IV Workflow, and manual compounding software automation solution. Health
Robotics’ second generation solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have
been found [through scientific and peer-reviewed studies[1],[2]] to greatly contribute to
ease hospitals’ growing pressures to improve patient safety[4], increase throughput, and
contain costs[1]. Through the effective and efficient production of sterile, accurate,
tamper-evident and ready-to-administer IVs, Health Robotics’ medical devices and
integrated workflow solutions help hospitals eliminate life-threatening drug[1] and
diluent[1] exchange errors, improve drug potency[5], decrease other medical mistakes and
sterility risks, work more efficiently[1], reduce waste and controlled substances’
diversion, and diminish the gap between rising patient volume/acuity, and scarce nursing
and pharmacy staff. For more information, please visit: http://www.health-robotics.com

————————————————–

1. Asparaginase. Azacitidine, Bendamustin, Bevacizumab, Bleomycin, Bortezomib,
Busulfan, Carboplatin, Cetuximab, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide,
Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Docetaxel, Doxorubicin,
Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Gemtuzumab, Ibrituximab,
Idarubicin, Ifosfamide, Infliximab, Irinotecan, Ixabepilone, Liposomal Doxorubicin,
Melphalan, Mesna, Methotrexate, Mitomycin, Mitoxantrone, Mitumomab, Nelarabine, Nimustine,
Ofatumumab, Oxaliplatin, Paclitaxel, Panitumumab, Pemetrexed, Raltitrexed, Rituximab,
Streptozocin, Tabalumab, Thiotepa, Topotecan, Trabecitabine, Trastuzumab, Treosulfan,
Vinblastine, Vincristine, Vindesine and Vinorelbine.

2. Am J Hosp Pharm 46(11): 2286–93 1989. St. Boniface Hospital, Winnipeg.

3. http://www.intelligenthospitals.com/news.html

4. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger,
Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and
Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard
Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

5. Validation of an automated method for compounding monoclonal antibody patient
doses: case studies of Avastin(R), Remicade(R), and Herceptin(R). Peters, Capelle,
Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

        For additional information, please contact:
        Claudia Perez
        perez@health-robotics.com
        Phone +1-786-417-1251

SOURCE Health Robotics


Source: PR Newswire